Hydrocephalus and vasculitis delay therapeutic responses in tuberculous meninigitis: Results of Haydarpasa-III study
Conclusions: In the absence of hydrocephalus or vasculitis, one week of anti-tuberculosis treatment seems to be adequate for the resolution of TBM symptoms. Hydrocephalus and vasculitis delay the resolution of TBM symptoms in response to antimycobacterial treatment.
[Vanguard] Abuja -The Federal Government said it had concluded arrangements to convert tuberculosis' diagnostic machines in the country coronavirus' detection machines.
[The Herald] Government is working on utilising tuberculosis and HIV testing machines to run Covid-19 tests.
[Daily Trust] Nigeria is looking to convert more than 300 GeneXpert machines used to tuberculosis diagnosis for use in coronavirus testing in three weeks at most, health minister Osagie Ehanire said on Tuesday.
Viral triggers have been implicated in the pathogenesis of cardiac allograft vasculopathy (CAV), the Achilles heel of heart transplantation (HT). Cytomegalovirus is associated with impaired coronary endothelial function, and in pediatric HT patients a variety of viruses, particularly adenovirus, are associated with graft dysfunction or loss. Hepatitis B virus (HBV) is associated with vasculitis and vascular processes in non-HT patients. We thus investigated the association between HBV seropositivity and CAV after HT.
Aim of the study to assess the clinical relevance of vasculitis, in terms of survival and cardiac allograft vasculopathy development in the mild forms of rejection in HTx adult patients
Publication date: Available online 30 March 2020Source: The Lancet HIVAuthor(s): Harriet Mayanja-Kizza
Publication date: Available online 30 March 2020Source: The Lancet HIVAuthor(s): Kelly E Dooley, Radojkam Savic, Akshay Gupte, Mark A Marzinke, Nan Zhang, Vinodh A Edward, Lisa Wolf, Modulakgotla Sebe, Morongwe Likoti, Mark J Fyvie, Innocent Shibambo, Trevor Beattie, Richard E Chaisson, Gavin J Churchyard, DOLPHIN Study Team
Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.
Researchers in a handful of countries are testing a century-old tuberculosis vaccine to see if it can give a boost to the immune system to help it fight off the novel coronavirus now causing the COVID-19 pandemic.
Conclusion: Frontofacial monobloc advancement with distraction osteogenesis provides long-term midface bone stability. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.